Arabian Journal for Science and Engineering, Год журнала: 2025, Номер unknown
Опубликована: Апрель 9, 2025
Язык: Английский
Small Methods, Год журнала: 2025, Номер unknown
Опубликована: Янв. 28, 2025
Abstract Non‐small cell lung cancer (NSCLC) has a strikingly high incidence rate globally. Although immunotherapy brings great breakthrough in its clinical treatment of NSCLC, significant challenges still need to be overcome. The development novel multi‐functional nanomedicines the realm tumor offers promising opportunities for NSCLC patients, as exhibit advantages, including specific targeting cells, improved drug bioavailability, reduced systemic toxicity, and overcoming immune resistance. In this review, core features current status strategies checkpoint blockade, antibody–drug conjugates, engagers, adoptive vaccines, are surveyed. Particular emphasis is placed on recent that boost these strategies. Nanomedicine can provide perspectives immunotherapy.
Язык: Английский
Процитировано
1
Bioactive Materials, Год журнала: 2025, Номер 48, С. 29 - 42
Опубликована: Фев. 13, 2025
Язык: Английский
Процитировано
1
Chemical Engineering Journal, Год журнала: 2025, Номер unknown, С. 161412 - 161412
Опубликована: Март 1, 2025
Язык: Английский
Процитировано
1
Advanced Science, Год журнала: 2025, Номер unknown
Опубликована: Янв. 10, 2025
Abstract Small molecules as nanomedicine carriers offer advantages in drug loading and preparation. Selecting effective small for stable nanomedicines is challenging. This study used artificial intelligence (AI) to screen combinations self‐assembling nanomedicines, employing physiochemical parameters predict formation via machine learning. Non‐Steroidal Anti‐Inflammatory Drugs (NSAIDs) are identified antineoplastic drugs, with high loading. Nanomedicines, PEG‐coated indomethacin/paclitaxel (PiPTX), laminarin‐modified (LiDOX), developed extended circulation active targeting functions. Indomethacin/paclitaxel iDOX exhibits pH‐responsive release the tumor microenvironment. These enhance anti‐tumor effects reduce side effects, offering a rapid approach clinical development.
Язык: Английский
Процитировано
0
Journal of Materials Chemistry B, Год журнала: 2025, Номер unknown
Опубликована: Янв. 1, 2025
In this study, a novel ASGP-R targeted contrast agent has been developed for liver cancer diagnosis, which exhibits high imaging efficacy and great biosafety, holding promise as MRI of human cancer.
Язык: Английский
Процитировано
0
Acta Biomaterialia, Год журнала: 2025, Номер unknown
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
0
Colloids and Surfaces A Physicochemical and Engineering Aspects, Год журнала: 2025, Номер unknown, С. 136461 - 136461
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
0
Advanced Materials, Год журнала: 2025, Номер unknown
Опубликована: Фев. 17, 2025
Strategically targeting lymph nodes (LNs) to orchestrate the initiation and regulation of adaptive immune responses is one most pressing challenges in context vaccination. Herein, a series polymer-TLR agonist conjugates (PTACs) developed investigate impact dendritic-topological characteristics on their LN activity vivo, molecular weight (MW) pharmacokinetics support homing. Notably, dendritic 6-arm PTAC with MW 60 kDa (6A-PTAC-60k) rapidly delivered cargo draining LNs after administration peripheral tissues. Specifically, this topologic structure ameliorated behavior within lymphatic vessels LNs, including an elevated amount TLR7/8 improved distribution pattern among barrier cells cells, increased permeability, prolonged retention. Furthermore, 6A-PTAC-60k formulation induced broad antibody T cell responses, enhancing vaccine immunogenicity suppressing tumor growth. The results revealed that both topology polymers are crucial factors for immunoadjuvant functional which, turn, enhanced formulation. This study may provide chemical structural basis optimizing design delivery systems.
Язык: Английский
Процитировано
0
Precision medicine and engineering., Год журнала: 2025, Номер unknown, С. 100020 - 100020
Опубликована: Фев. 1, 2025
Язык: Английский
Процитировано
0
Materials Today Bio, Год журнала: 2025, Номер 31, С. 101601 - 101601
Опубликована: Фев. 20, 2025
Over the last two decades, molecular biology advances have revealed gut microbiota's active and crucial role in colorectal cancer (CRC) pathogenesis its dysregulation during tumorigenesis. This understanding has underscored urgency of exploring novel therapeutic approaches to address challenges posed by CRC. Among these approaches, nanosynergistic therapies, with their potential modulate microbiota, increase drug bioavailability stability, reduce side effects, emerged as a promising avenue. Furthermore, efficacy nanotechnology-based can be enhanced combining them different methods, including chemotherapy, radiotherapy, immunotherapy, photothermal therapy, sonodynamic therapy. Herein, recent progress nano synergistic therapy been reviewed, focusing on synergy between microbiota nanotechnology CRC treatment. Additionally, diverse applications nanoparticles analyzed provide innovative ideas effective solutions for developing highly treatment strategies.
Язык: Английский
Процитировано
0